MedTrace Logo

Maxillary Sinus Elevation and Simultaneous Implant Placement

NCT03252366 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-08-17

No results posted yet for this study

Summary

using gel foam \[ absorbable gelatin \] in maxillary sinus elevation which act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus and its advantages for patients undergoing maxillary sinus elevation with simultaneous implant placement as regards the implant stability and amount of bone height gain compared to conventional maxillary sinus elevation by xenograft.

Conditions

  • Maxillary Sinus

Interventions

DEVICE

GELFOAM

* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla. * A diamond bur will be used to make a rectangular osteotomy. * The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement. * Implant stability will be measured by osteal device * implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure. * The flap will then be closed using interrupted 4/0 resorbable sutures.

DEVICE

xenograft

* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla. * A diamond bur will be used to make a rectangular osteotomy. * The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement. * Implant stability will be measured by osteal device * implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure. * The flap will then be closed using interrupted 4/0 resorbable sutures.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-09-30
Completion
2017-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03252366 on ClinicalTrials.gov